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INTRODUCTION
Gene transfer is a promising way to treat recessive disorders. 
Adeno-associated virus (AAV) is an efficient and advantageous type 
of vector to deliver DNA into various tissues such as liver or skeletal 
muscle. AAV vectors are nonpathogenic, demonstrate very low lev-
els of host genome integration, effectively transduce muscle fibers, 
and initiate long-term transgene expression. However, the packag-
ing capacity of the AAV vector is limited to ~5 kb, preventing the 
encapsidation of large genes.1 To bypass this limitation, different 
strategies have emerged in the recent years for the in vivo expres-
sion of full-length large transgenes after rAAV delivery.
In the first described method called concatemerization-splic-
ing,2–6 the reconstitution of full-length transgenes occurs following 
in vivo administration of two rAAV vectors. One vector is composed 
of a promoter, the 5’ portion of the transgene and a donor splic-
ing signal sequence (5’ vector); and the second vector exhibits an 
acceptor splicing signal sequence, the remaining 3’ portions of 
the transgene, and a polyA sequence (3’ vector). After coinfection 
and conversion into a double strand, concatemerization occurs 
by intermolecular recombination mediated by inverted terminal 
repeat (ITR) sequences of the two rAAV genomes.7,8 Some of these 
events establish the desired transcriptional cassette such that the 
ITR concatemerization junction is removed by splicing, effectively 
generating a full-length messenger/protein from what was origi-
nally two distinctly transduced rAAV genomes. Another strategy 
based on overlap between two rAAV genomes carrying overlapping 
fragments has been proved efficient to reconstitute a split trans-
gene by homologous recombination (HR).3,9 Interestingly, it has 
been shown that, HR was the underlying mechanism of obtaining a 
protein from the use of a rAAV cassette constituted by a full-length 
large cDNA (up to 8.9 kb) packaged into an AAV5 capsid.10–12 Indeed, 
in that case the capsid packages partial products from both ends 
of a full-length large cDNA and that the reconstitution happens by 
HR between overlapping regions of two vectors.13–15 As this strategy 
relies on the intracellular reassembly of genome fragments pro-
duced during the ineffective packaging of oversized AAV genomes, 
this vector context was termed “fragment AAV (fAAV)”.16 In addi-
tion to these methods, a combination of both concatemerization-
splicing and HR referred as hybrid dual AAV vector system was also 
efficient in generating a large protein from a large cDNA.17,18 In that 
case, in addition to carry splicing sequences, the two AAVs include a 
homologous sequence.
Dysferlinopathies regroup different clinical presentations includ-
ing limb girdle muscular dystrophy type 2B (LGMD2B), Miyoshi 
myopathy (MM), and distal anterior compartment myopathy (DMAT). 
They are caused by mutations in the DYSF gene, which encodes a 
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Recombinant adeno-associated virus (rAAV) is currently the best vector for gene delivery into the skeletal muscle. However, the 
5-kb packaging size of this virus is a major obstacle for large gene transfer. This past decade, many different strategies were devel-
oped to circumvent this issue (concatemerization-splicing, overlapping vectors, hybrid dual or fragmented AAV). Loss of function 
mutations in the DYSF gene whose coding sequence is 6.2kb lead to progressive muscular dystrophies (LGMD2B: OMIM_253601; 
MM: OMIM_254130; DMAT: OMIM_606768). In this study, we compared large gene transfer techniques to deliver the DYSF gene 
into the skeletal muscle. After rAAV8s intramuscular injection into dysferlin deficient mice, we showed that the overlap strategy is 
the most effective approach to reconstitute a full-length messenger. After systemic administration, the level of dysferlin obtained 
on different muscles corresponded to 0.5- to 2-fold compared to the normal level. We further demonstrated that the overlapping 
vector set was efficient to correct the histopathology, resistance to eccentric contractions and whole body force in the dysferlin 
deficient mice. Altogether, these data indicate that using overlapping vectors could be a promising approach for a potential clinical 
treatment of dysferlinopathies.
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237 kDa tail-anchored membrane protein called Dysferlin. DYSF is 
composed of 55 exons spanning over 150-kb of genomic DNA and 
is expressed as a 6.2-kb cDNA predominantly present in skeletal 
muscle and in peripheral blood monocytes.19 Dysferlin belongs to 
the family of ferlins and is composed of seven C2 calcium-depen-
dent phospholipid-binding domains, arrangement of specific FER 
and DYSF domains, and a transmembrane domain. A major role of 
dysferlin in muscle membrane repair was demonstrated.20 Besides 
this particular function, dysferlin was proposed to carry out addi-
tional roles associated with vesicle fusion events such as T-tubule 
integrity21 or trafficking of membrane-associated proteins.22
There is, to date, no effective therapy for dysferlinopathies. The 
application of gene therapy is complicated by the fact that the dys-
ferlin cDNA exceeds the encapsidation capacity of the AAV vectors. 
Consequently, large-gene methods have started to be applied for 
these diseases. Indeed, two studies that used the concatemeriza-
tion-splicing and “fragment” HR strategies demonstrated dysferlin 
full-length expression in vivo. The efficient expression of dysferlin 
was associated with restoration of membrane repair capacity of 
myofibers and restoration of physiologic function of muscles.12,23 
Here, we present a comparative study to evaluate the relative effi-
ciency of different large gene transfer methods using dysferlin as 
a model. In addition to the vectors for the concatemerization-
splicing method previously generated and referred as Set 1,23 we 
constructed new two dual AAV vector sets (Sets 2 and 3) and a vec-
tor with the full-length cDNA to generate the “fragmented” pack-
aged vector genomes (fAAV). To compare the efficiency of muscle 
transduction and level of expression of the full-length protein, we 
performed intramuscular (IM) injections of all the vectors into the 
Tibialis anterior (TA) muscle of dysferlin deficient mice (B6.A-Dysf prmd, 
also called Dysf prmd). From the comparison, the set of vectors driving 
the best expression of dysferlin was used for dose-effect and func-
tional analyses after systemic administration.
ReSUlTS
Packaging efficiency of the different strategies
To compare the different large gene transfer methods, we con-
structed several cassettes for full-length human dysferlin delivery 
using a single or a combination of two AAV vectors (Figure 1a). The 
first set of vectors (Set 1) was derived from a previously described 
pair of vectors, and generally has been termed concatemerization-
dependent trans-splicing vectors.23 The 5’ cassette of this set is com-
posed of a muscle-oriented promoter (C5-12), a chimeric intron 
β-globin, the first half of the dysferlin cDNA (from exon 1 to exon 28) 
and half the intron 28. The 3’ cassette carries the second half of intron 
28 followed by the second half of the dysferlin cDNA. The second set 
of large gene delivery vectors (Set 2) was derived from the first set 
with the modification that the intron 28 was present in full in both 
cassettes. The consequence is that the two vectors overlap with 254 
nt. The third vector combination (Set 3) is composed of overlapping 
vectors where the 5’ vector carries the dysferlin cDNA from exon 1 to 
the middle of exon 30 and the 3’ vector from the middle of exon 23 
to exon 55, thereby exhibiting an overlap of 859 nt. Finally, a single 
vector with a full-length dysferlin cDNA cassette was constructed 
(fAAV vector). Important for our comparisons, all of these constructs 
carry the same promoter and regulatory sequences. In addition, the 
sequence immediately upstream of the dysferlin start codon was 
modified to correspond to a strong Kozak sequence. All cassettes 
were packaged into a rAAV2/8, an efficient serotype for skeletal mus-
cle transduction and tittered by quantitative polymerase chain reac-
tion (PCR) using conserved sequences within the AAV ITR.
To characterize the packaged genomes of these different sets, an 
alkaline gel electrophoresis in denaturing condition was performed 
on extracted genomes from the vector preparations (Figure 1b, 
upper panel). For all vectors included in the Sets 1 and 3, the major 
band was at the expected size, around 4.5 kb. The result was con-
firmed by Southern blot using an ITR probe (Figure 1b, lower panel). 
However, a different pattern was observed for packaged fAAV 
genomes which demonstrated a heterogeneous ladder of DNA 
species from 1 to 4.5 kb in size (Figure 1b). In that case, truncated 
genome fragments are packaged, with a preference for smaller 
species, when the genome exceeds the AAV packaging capacity. 
Following this observation, a new batch of fAAV vector was pre-
pared. In contrast to the first one which contained all the fractions 
collected during the second round of CsCl density gradients during 
purification, this second batch contained only the most dense frac-
tions of the CsC1 gradient that are enriched in the largest packaged 
genomes (Figure 1c). Next, fAAV Batch 1 and Batch 2 were injected 
into the TA muscle of Dysfprmd male mice (n = 4) at an equivalent 
dose (9e8 viral genome (vg) per muscle) to compare their relative 
efficiency. The expression of dysferlin was evaluated 1 month later 
at protein levels (Figure 1d). Not surprisingly, it was observed that 
the enrichment of fAAV Batch 2 with the largest packaged genomes 
allows a more efficient expression of dysferlin (Figure 1d).
Comparison of dysferlin expression of different therapeutic 
strategies in vivo after IM injection
To compare the transduction efficiency of the different approaches, 
IM injection of rAAV2/8 preparations of set of vectors were per-
formed in TA muscles of 1-month-old Dysfprmd male mice (n = 4) at 
the dose of 1.3e10 vg per muscle. It should be noted that this model 
has a moderate myopathology with the first pathological signs 
being visible at 2 months of age. Therefore, at the time of injection, 
the Dysfprmd TA muscles show no signs of pathology. The expression 
of dysferlin was compared 1 month later by qRT-PCR and Western 
blot analysis. For quantification of the concatamerization-splicing 
event for Sets 1 and 2, the qRT-PCR analysis was performed with a 
pair of primers (F.exon28, R.exon29) coupled with a specific probe 
(P.Exon28-29) designed to overlap the Exon 28–29 junction. For Set 
3 and fAAV, due to the large homologous regions shared between 
cassettes, it was not possible to design a qRT-PCR amplicon that can 
be specific of reconstituted dysferlin. The results showed that Set 
1 led to a similar level of mRNA compared to the human control, 
while an approximate 50% reduction was observed using the Set 2 
vectors (Figure 2a).
Western blots performed using N-terminal (Romeo) or C-terminal 
(Hamlet) dysferlin antibodies revealed the presence of a band at the 
expected size (237 kDa) in all injected muscles that was absent in 
phosphate-buffered saline (PBS) control-treated mice (Figure 2b). 
The western blot showed substantial differences in the expression 
level from each vector Set. Sets 1 and 2 were somewhat similar con-
sidering the variability of western blot quantification with both anti-
bodies, yielding the lowest levels of Dysferlin (Figure 2 and Table 1). 
In contrast, both Set 3 and fAAV vectors mediated enhanced 
Dysferlin transduction with Set 3 demonstrating an approximate 
4–10-fold increase compared to Batch 2 fAAV (Figure 2; Table 1).
Immunohistofluorescence was performed on muscle sections 
for each of the above conditions using the Hamlet dysferlin anti-
body (Figure 2c). A dysferlin staining that correlated with the WB 
quantification can be observed. The lowest expression levels was 
obtained for Sets 1 and 2, while Set 3 showed a high proportion of 
positive fibers and a high level of expressed protein in transduced 
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fibers. A colabelling of dysferlin and RyR, a protein of the sarcoplas-
mic reticulum in close proximity with T-tubules, was also performed, 
showing no difference between the conditions (Figure 2d).
Systemic injection of the HR vectors
Given the efficient performance of Set 3 vectors, as well as the 
additional complications moving fAAV into the clinic, Set 3 
Figure 1  The different approaches for adeno-associated virus (AAV)-mediated dysferlin gene expression. (a) Schematic representation of the four 
strategies designed for dysferlin expression. The dysferlin FL cDNA (human isoform 8) was split into two viral vectors to evaluate concatemerization-
splicing (Set1), concatemerization-splicing plus overlapping vectors (Set 2) and overlapping (Set 3) approaches. Alternatively, a full-length dysferlin 
expression cassette was used to generate a fragmented rAAV preparation (fAAV vector). All cassettes were packaged into a rAAV2/8 vector using 
standard triple transfection protocol, following by CsCl Density gradient purification and Dot-Blot oriented selection of AAV-rich fractions. The size of 
each cassette from inverted terminal repeat (ITR) to ITR and the size of the homologous regions for sets 2 and 3 are mentioned. ITR are represented by 
large black arrows. Splicing sites (donor and acceptor) are indicated by grey dots. (b) Characterization of AAV vectors. The genomes were extracted 
from rAAV8 vector preparations (Set1, Set3, and fAAV batches) and analyzed by denaturing alkaline gel electrophoresis. Set 2 was omitted from the 
analysis since it is structurally related to Set 1. Upper panel: direct visualization of the gel. Lower panel: Southern blot hybridized with an ITR probe. 
(c) Alkaline Agarose Gel analysis of genomes isolated from fAAV Batch 1 and fAAV Batch 2 rAAV8 preparations. The fractions 2 to 7 from fAAV Batch 2 
and pooled fractions of fAAV Batch 1 were analyzed by alkaline gel electrophoresis. The selected fractions corresponding to the largest genomes are 
indicated by the X symbol. (d) IM delivery of rAAV8 fAAV Batch 1 and fAAV Batch 2 was performed in the left TA muscle of 4-week-old Dysfprmd with an 
equal dose of each vector. Anti-dysferlin western blot was performed using Hamlet antibody (n = 4 for each batch). Actin was used for normalization.
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vectors were used to reconstitute dysferlin after a systemic injec-
tion in the tail vein of 1-month-old Dysfprmd mice (n = 3) at the 
dose of 9e13 vg/kg.
One month after injection, a collection of muscles (Tibialis ante-
rior (TA), Psoas (Pso), Triceps brachii (Tri), Deltoid (Del), Gastrocnemius 
(Ga), Gluteus (Glu), Biceps brachii (Bi), Quadriceps femoris (Qua)), the 
Figure 2 Comparison of transgene expression after intramuscular injection. The left TA muscle of 1-month-old Dysfprmd mice was injected with 1.3e10 
vg of each Set of vectors (ratio 1:1). The right TA muscle was injected with PBS as a control (n = 3–4/group). (a) Dysferlin mRNA level was measured 
by quantitative real-time polymerase chain reaction (qRT-PCR) using a specific probe and primer set specific of concatemerization-splicing and 
intronic HR vectors with primers flanking exon28-29 junction and junction overlapping probe. Dysferlin mRNA levels were normalized by acidic 
ribophosphoprotein (Rplp0) mRNA level. Data are significantly different compared to untreated deficient mice. Data are given as mean ± SEM; 
***P < 0.001. (b) Western blot analyses were performed with N-terminal (Romeo) and C-terminal (Hamlet) domain specific antibodies directed against 
dysferlin and normalized by an anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody. (c) Immunohistofluorescence for detection 
of dysferlin using Hamlet antibody. The difference in proportion of dysferlin between the sarcolemma and the internal membrane compartment 
after transfer is something that is always observed whatever the strategy. The reason underlying this particularity is still unclear. Scale bar = 200 µm. 
(d) Colocalization staining was performed using Romeo antibody in red (upper panel) and RyR antibody in green (middle panel). Merge images showing 
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heart, and the liver were sampled for analysis. RNA extracted from 
treated mice was converted to cDNA and the region including the 
vector overlap was sequenced. The sequenced region was 100% 
identical to the dysferlin transcript encoded by the transgene cas-
settes, confirming that the dysferlin expression originated from the 
vectors (data not shown). We observed efficient full-length dys-
ferlin expression in all treated muscles compared to C57BL/6 mice 
(Figure 3a). Dysfprmd mice treated with Set 3 vectors demonstrated 
positive dysferlin expression by immunostaining using a monoclo-
nal antibody against dysferlin compared to noninjected mice, with 
some fibers presenting stronger expression of dysferlin than other. 
In wild-type mice, dysferlin was mainly localized at the sarcolemma 
and, at a reduced level, in the cytoplasm associated to T-tubules.24 
In treated deficient mice, labelling of the newly synthesized dysfer-
lin was strong both at the sarcolemma and in the cytosol (Figure 3b).
The histological state of treated mice was evaluated in hematox-
ylin-phloxine-saffron–stained sections (Figure 3c). The expression 
of dysferlin was associated with a decrease of centralized nuclear 
fibers in all collected muscles compared to the noninjected defi-
cient mice (Figure 3d). Importantly, even though a significant level 
of full-length dysferlin protein was expressed with this high dose 
(9e13 vg/kg), a full phenotypic restoration of dysferlin deficient mice 
was not reached after one month of expression since some level of 
centronucleation remained (Figure 3c,d). In addition, expression 
of dysferlin was checked in other organs. WB analyses showed a 
consequent level of expressed protein into the heart and a weak 
expression in liver tissue (Figure 4a). No cardiac or hepatic histopath-
ological abnormalities were observed in treated mice (Figure  4b) 
and no increased activity level of seric enzymes (alanine (ALAT) 
and aspartate (ASAT) aminotransferase) was observed between 
untreated and treated deficient mice (Figure 4c).
A dose of 4.5e13 vg/kg of the Set 3 allowed long-term functional 
rescue
Because of the absence of a full histological recovery upon following 
vector mediated dysferlin restoration/overabundance (Figure 3), we 
reasoned that there was the possibility that the quantity of dysferlin 
might be too high since it was previously shown that overexpres-
sion of dysferlin was associated with toxicity.25 Therefore, we per-
formed experiments with different amounts of vectors to determine 
the required minimal dose of dysferlin to improve the pathology 
using the Set 3 vectors. Three doses, corresponding to half (4.5e13 
vg/kg), a third (3e13 vg/kg), or a quarter (2.3e13 vg/kg) of the initial 
dose (9e13 vg/kg), were tested by systemic administration in the tail 
vein in 1-month-old Dysfprmd mice (n = 4/group) and were analyzed 1 
month or 1 year postinjection.
Blood and the most affected muscles in Dysf prmd (TA, Pso, and Glu) 
were sampled for dysferlin analysis 1 month after the Set 3 AAV vec-
tor administration. We detected the expected 237 kDa band of the 
dysferlin protein in all injected groups by WB analysis (Figure 5a). A 
quantification using vinculin as a loading control was performed in 
Glu, Pso, and TA muscles samples (Figure 5b). The efficiency of expres-
sion of dysferlin presented variations according to the muscles. The 
4.5e13 vg/kg dose led to a level of dysferlin in TA corresponding to 
the endogenous level of dysferlin in a wild-type (WT) muscle. For the 
same dose, compared to the WT condition, the quantity of expressed 
dysferlin was decreased twofold in the Pso muscle and approximately 
twofold elevated in the Glu muscle (Figure 5b). The dysferlin expres-
sion corresponding to two lowest injected doses (3e13 or 2.3e13 vg/
kg) was lower as expected. On the muscle sections, the level of trans-
duction is related to the quantity of injected vectors (Figure 5c, upper 
panel). Inflammatory infiltrates was checked by immunohistofluo-
rescence using CD8 and CD11b antibodies. No positive CD8 cell was 
observed in any conditions (data not shown). CD11b labeling showed 
clusters of positive cells in noninjected deficient mice whereas in 
treated mice, only few remaining cells were detected in all treated 
samples, suggesting a decrease of inflammation after rAAV delivery 
(Figure 5c, lower panel).
At the histological level, the presence of dysferlin was associated 
with a decrease of centralized nuclear fibers in TA and Glu muscles, 
but not in the Pso muscle (Figure 5d). This could be explained by 
the fact that the expression of dysferlin in the Pso muscle of treated 
mice did not reach physiological levels. After treatment with Set 3 
vectors (Figure 1), the creatine kinase (CK) level was measured in 
serum. Regardless of the administered dose, the level of CK was 
lower than that determined in the nontreated mice, with a level very 
close to the WT condition for the highest injected dose (4.5e13 vg/
kg dose; Figure 5e).
To evaluate the functional rescue of muscles after rAAV dysferlin 
treatment using Set 3 vectors, a functional eccentric assay, named 
large-strain injury (LSI), was performed for the three doses.26,27 
This assay was designed to evaluate the ability of the TA muscle to 
recover from eccentric exercise and intrinsically, the sarcolemma 
ability to respond to this exercise. The LSI assay was performed 
in vivo in the TA muscle of Set 3 treated mice. The membrane dam-
age was induced by 15 repetitive eccentric contractions and mus-
cles were collected 3 days later. Evans Blue dye (EBD) was injected 
the day before muscle harvest to stain the sensitive-to-damage 
fibers. As we previously reported, the dysferlin-deficient muscles 
showed a very significant increase in EBD positive fibers compared 
to WT mice.28 In all muscles treated with Set 3 vectors, the abun-
dance of EBD positive fibers was significantly decreased by at least 
fivefold (Figure 5f ).
The long-term outcome was analyzed in mice injected with a 
quarter or a half of the maximal dose after 1 year. The dysferlin pro-
tein level obtained with the half dose is close to the WT one whereas 
it is lower and almost absent in some mice injected with a quarter of 
the maximum dose (Figure 6a,b). An increase of the muscle weight 
was observed with both doses (Figure 6c). At the histological level, 
the positive effect of the injection can be clearly observed with a 
nice correlation with the level of dysferlin obtained after injection 
(Figure 6d). The 1/2 dose histology is close to the WT condition while, 
with the ¼ dose, the mice with less dysferlin present the worst his-
tology. Finally, assessment of the global force of the mice was per-
formed using the escape test (Figure 6e). The data showed a very 
significant restoration of the global force for the highest dose (0.141 
Table 1 Quantification of dysferlin western-blot performed 
with Hamlet and Romeo antibodies and expressed in  
percentage compared to WT
WT NI Set1 Set2 Set3 fAAV
N-ter 
Romeo Ab
100% 5% 27% 40% 664% 60%
SEM ± 0 ± 1.3% ± 10.3 ± 8.4 ± 228% ± 27.5%
C-ter 
Hamlet Ab
100% 1.34% 28.74% 17.76% 378.83% 41.67%
SEM ± 0 ± 0.7% ± 11.3% ± 3.1% ± 128% ± 23.8%
The blots were performed in duplicate with n = 4.
SEM, standard error of the mean.
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N/g) versus WT (0.149 N/g) and compared to Dysfprmd (0.108 N/g). 
These values indicated that the mice injected with ½ dose reached 
95% of the WT force and therefore correspond to an improvement 
of 81% compared to the Dysfprmd mice (72% of the WT value).
All together, these data show that, the highest administered dose 
of Set 3 vectors (4.5e13 vg/kg) allowed the restoration of physiologi-
cal levels of dysferlin in treated mice, leading to an improvement of 
the dystrophic phenotype including restoration of the whole body 
force nearly to the WT level.
DISCUSSION
Several studies reported the development of strategies to over-
come the packaging limitation of wild type AAV vectors (5-kb) for 
the transfer of large transgenes.2,3,6,29–32 Despite an early suggestion 
that some serotypes may be tolerant for encapsidation of larger 
genomes,10,11 it appears that all these strategies rely on intermolec-
ular recombination, exploiting the fact that the AAV genomes are 
recognized as targets for host DNA repair pathways.1,16 Depending 
on the case, this event could happen between ITR sequences during 
concatemerization,2,3,5,6,23,29–37 between overlapping sequences of 
two distinct cassettes,3,15,36,38–41 or between common regions of frag-
ments of the same initial cassette for fragmented/oversized.10–16,36 
The recombination could, in addition, be coupled with a splicing 
process as in hybrid vectors.17,18,36,39
In the literature, these vector strategies for large gene transfer 
were evaluated in different contexts, with different genes of varying 
sizes, and in different cell types and/or target tissues, including skel-
etal muscle3,16,18,39 or in the retina.15,16,36 In this study, we undertook a 
Figure 3 Systemic administration of HR-based vectors transduces effectively the muscles of dysferlin deficient mice and improves the phenotypes of 
the muscles. Set3 rAAV8 (9e13 vg/kg) was delivered in the tail vein of 1-month-old Dysfprmd mice (n = 3/group). (a) Detection of transgenic dysferlin 
(237 kDa) by Hamlet western blot in all sampled muscles. Bi, Biceps brachii; Del, Deltoid; Ga, Gastrocnemius; Glu, Gluteus; Pso, Psoas; TA, Tibialis anterior; 
Tri, Triceps brachii; Qua, Quadriceps femoris. (b) Immunostaining performed with a dysferlin C-terminal (Hamlet) domain specific antibody in TA muscle 
compared to WT muscle. No signal was detected in phosphate-buffered saline–injected deficient mice or with secondary antibody control. Scale bar 
= 40 µm. (c) Representative area of hematoxylin-phloxine-saffron counterstained muscle sections of Glu, Pso, and TA muscles from WT, untreated, and 
treated deficient mice. Scale bar = 50 µm. (d) Centralized nuclear fibers (CNF) index. Values are expressed in CNF per mm2 of muscle section. Data are 
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comparison in skeletal muscle using the 6.2-kb long dysferlin cDNA 
as a model and the AAV8 capsid. This study built on our previous 
results demonstrating reconstitution of dysferlin expression by 
concatemerization-splicing vectors (Set 1),23 albeit with a modest 
efficiency following systemic administration. In this comparative 
study, the overlapping AAV large gene transduction strategy (Set 3) 
was identified as the most potent approach for dysferlin restoration.
The overlapping strategy has been previously used in skeletal 
muscle to transfer either β-galactosidase by IM injection or mini-
dystrophin following both IM3,18,38,39 and intravenous injection (IV) 
administration.40,41 Early experiments3,38 were performed using 
AAV2 which explained the low efficiency of transduction, but 
using the alternative serotypes such as AAV6 or AAV9 the efficiency 
was relatively high. In particular, 80% of fibers expressed the LacZ 
transgene after IM transfer of an overlapping vector set using an 
872 bp alkaline phosphatase coding sequence (AP) overlapping 
sequence38 and 90% positive fibers were observed after IM transfer 
of a vector set with a 400 bp overlap of dystrophin sequence.39 The 
same vector set led to 35–40% positive fibers following IV admin-
istration40 and demonstrated therapeutic efficiency.41 In our study, 
we demonstrated that full-length dysferlin protein was restored and 
over-expressed (0.5- to 2-fold) compared to the WT level, depend-
ing on the muscle following systemic delivery of our overlapping 
vector set (Set 3, Figures 3, 5 and 6). Furthermore, restoration of 
histological deficiencies and whole-body force were observed to 
reach nearly the WT condition with a dose 4.5e13 vg/kg (Figure 6). 
Altogether, these results reinforce that the AAV overlapping vector 
large gene delivery strategy is of great interest to target the skeletal 
muscle for the treatment of muscular dystrophies.
In previous works, the overlapping vector strategy was used to 
transfer eye-disease–related genes, MYO7A or ABCA4, to the retina 
following subretinal injection.15,36 Of note, these vectors efficiently 
transduced retinal pigment epithelial cells but not neuronal pho-
toreceptors (PR), suggesting that the nature of the cells can impact 
the efficiency of large transgene reconstruction.36 It was proposed 
that the lack of overlapping vector transduction efficiency in the PR 
is a consequence of the low levels of HR in postmitotic neurons.42 
Downregulation of the HR factors is one hallmark associated with 
the exit from the cell cycle and terminal differentiation in neurons42 
and muscle fibers,43 a fact that may underlay the permissivity of 
these tissues to AAV large gene transduction. However, the absence 
of canonical HR in nondividing cells seemingly contradicts the 
decent efficiency of the different AAV vector genome reconstruc-
tion approaches observed in skeletal muscle and, therefore, sug-
gests that the necessary repair factors, and or mechanism, remain 
uncharacterized. In fact, whereas AAV transduction seems to rely 
on the inhibition of the MRN (Mre11, Rad50, Nbs1) complex,43–45 it 
has been shown that reconstitution of full-length transcript from 
fAAV genomes was dependent on the DNA strand-annealing pro-
tein Rad51C,16 a protein of the HR pathway that was shown to be 
less abundant in brain tissue than in skeletal muscle.46 Therefore, 
the differences of how the cellular machinery process AAV vectors 
in muscle and neurons, despite both being postmitotic cells, might 
depend on these DNA repair factors or others that remained to be 
determined. Beside this point, several studies pinpoint the impor-
tance of the nature of the overlapping sequence for the reconstitu-
tion efficiency in overlapping or hybrid strategies. For example, a 
recent study performed in the skeletal muscle observed a signifi-
cant difference in efficiency of four different set of dual AAV vec-
tors that have identical expression cassette except for the region of 
overlap.47
Interestingly, adding an overlapping region of 254 bp to the splic-
ing process in the Set 2 did not led to increase efficiency (Figure 2a, 
compares Set 1 and Set 2). The overlapping sequence present in Set 
2 has not been evaluated per se for its recombinogenic properties 
but it was shown in previous studies that combining splicing and 
HR is not always beneficial. Addition of two different overlapping 
sequences, a ~300 bp “highly recombinogenic” AP fragment or a 
77 bp fragment of AK (derived from the F1 phage genome in a study 
performed with two different transgenes (MYO7A and ABCA4) let 
to different outcomes36). In vitro and in vivo, the introduction of the 
AK sequence had a small positive effect, while introduction of the 
AP sequence introduction was very deleterious, although it was 
only evaluated in vitro.36 Therefore, combining an AAV trans-splicing 
strategy with a homologous fragment can impair or enhance the 
large gene transduction efficiency in a manner that requires further 
characterization.18,36 It remains possible that particular sequence 
combinations may influence the ITR intermolecular recombination 
event, the HR of the overlapping sequences, and/or alter the splic-
ing process, resulting in decreased efficiency.
Consistent with earlier reports, our data further confirmed that 
the “fragmented” full-length large gene transduction strategy 
relies on partial genome encapsidation and HR of the transduced 
fragments.10–14,16,36 Importantly, this notion is further supported by 
the demonstration that the transduction efficiency was directly 
related to the quality and size of the encapsidated vector genome 
fragments and not on the overall production titer. Therefore, care-
ful attention must be exercised when using fAAV preparations to 
exclude the nontransducing species, which is dependent up on the 
transgene size, to reduce the possibility of tittering genome frag-
ments incompetent for transduction (Figure 1). In fact, differences 
Figure 4 Ectopic transgene expression and assessment of enzymatic 
activity in serum. (a) Western blot of heart and liver tissues sampled from 
mice after Set3 systemic injection. Detection was performed with Hamlet 
antibody and GAPDH was used as a loading control. Three samples are 
shown. (b) Histology of heart and liver of injected mice (upper panels) 
compared to phosphate-buffered saline–injected control (lower panels). 
No abnormality was noticed in any of the samples. Scale bar = 200 µm. 
(c) Quantification of enzymes, ASAT and ALAT. Units are expressed in U/l. No 
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Figure 5 Determination of dose effect after systemic administration of HR-based vectors. Three doses (4.5e13, 3e13, and 2.3e13 vg/kg) corresponding 
to a half, a third, or a quarter of the maximum dose of Set3 vectors were injected in the tail vein in 1-month-old Dysfprmd mice (n = 4/group). Endpoint 
analysis occurred at 28 days post-rAAV delivery. (a) Western blot of TA muscles comparing the relative quantity of dysferlin in treated muscles. Dysferlin 
quantification was normalized by vinculin. (b) Western blot quantification of dysferlin, normalized by vinculin in analyzed muscles. Values are given in 
arbitrary unit (A.U.). Data are significantly different compared to WT mice. Data are given as mean ± SEM; n = 6 for Glu and Pso in WT and n = 4 for the others; 
***P < 0.001. (c) Immunofluorescence analysis of muscles injected with the three doses. Upper panel: DAPI counterstained anti-dysferlin (Romeo) 
staining performed on muscle sections of untreated and treated muscles of dysferlin deficient mice. Lower panel: 4’,6-diamidino-2-phenylindole 
(DAPI) counterstained anti-CD-11b staining to detect inflammatory response. White arrows indicate positive cells/cluster of cells. Scale bar = 50 µm. 
(d) Centralized nuclear fibers (CNF) index of Glu, Pso, and TA treated muscles (number of centronucleated fibers per mm2). Values are expressed in CNF 
per mm2 of muscle section. (e) Level of creatine kinase in serum of treated and untreated deficient mice compared to normal mice. Units are expressed 
in U/l. (f) Quantification of Evans Blue-positive fibers per mm2 on muscle sections of treated and untreated deficient mice compared to normal mice, 
3 days after LSI assay. Data are significantly different compared to untreated deficient mice. Data are given as mean ± SEM; n = 4 for each group; 
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in fAAV vector tittering may account for the performance variations 
when comparing the efficiencies of large gene transduction strate-
gies.16,48 Although the transduction efficiency of fAAV-dysferlin was 
approaching that of the Set 3 vectors (Figure 2c; Table 1), we chose 
not to pursue this strategy for the systemic studies due to clinical 
safety concerns as the fAAV genomes cannot be clearly defined 
and are difficult to titer accurately due to contamination by non-
transducing species.16 Regarding these packaged species, a ladder 
Figure 6 Long-term improvement of dysferlin-deficient mice with HR-based vectors. Half or the quarter of the maximum doses of Set3 vectors were 
injected in the tail vein of 1-month-old Dysfprmd mice (n = 4/group) to evaluate the long-term phenotype improvement. Endpoint analysis occurred at 
1-year post-rAAV delivery. Data are given as mean ± SEM; n = 4; *P < 0.05; **P < 0.01; ***P < 0.001. (a) Western blot of Qua muscles performed with Hamlet 
antibody and comparing the relative quantity of dysferlin in treated muscles. Dysferlin quantification was normalized by α-actin. (b) Quantification of 
the western blot, showing a level with the ½ dose reaching nearly the WT level. Values are given in AU. (c) Weight of the Qua muscles showing increases 
with both doses that are significant compared to the phosphate-buffered saline (PBS)-injected Dysfprmd mice. (d) Representative area of hematoxylin-
phloxine-saffron–stained muscle sections of Qua muscles from treated deficient mice compared to WT- and PBS-injected deficient mice. The order 
from left to right for the two doses is the same than in the western blot in (a), showing that the less improved muscles correspond to the mice with less 
dysferlin (i.e., the two middle muscles of the ¼ dose). Scale bar = 100 µm. (d) Assessment of the whole body force 1 year after injection, showing that 
mice injected with ½ dose reached 95% of the WT force (0.141 versus 0.149 N/g for the WT and compared to 0.108 N/g for the PBS-injected deficient 
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pattern was observed indicative of fragmented genomes of various 
sizes (Figure 1b). Additionally, it has been shown that the termina-
tion of packaging during AAV genome encapsidation is a relaxed 
process and thus, likely generates heterogeneous 5’ ends, perhaps 
in a sequence specific manner, a phenomenon that requires further 
characterization prior to consideration of fAAV as a therapeutic.49
The restoration of dysferlin levels, the significant improvement of 
dysferlin deficient muscle histology, the phenotypic recovery after 
an eccentric contraction protocol and restoration of the whole body 
force present one year after injection are very promising data for 
the use of AAV-mediated transfer of dysferlin cDNA as a therapeu-
tic strategy for dysferlinopathy. This point is of increasing interest as 
there is evidence that it might be beneficial to transfer the full-length 
dysferlin, rather than a truncated dysferlin variant termed minidys-
ferlin.28,50 First, dysferlin is composed of many unique domains that 
can support precise functions as suggested by their various and 
specific protein partners. This point suggests dysferlin may not be 
as amenable to domain deletions as has been noted for dystrophin, 
for which strategies relying on mini- or micro-dystrophin gene ther-
apy were shown to be functional even in large animal models.51,52 
Second, even though a naturally occurring minidysferlin has been 
identified in a patient presenting a mild dystrophic phenotype50; 
the data in animal models suggest that not all of the functions are 
recovered after gene transfer of this particular form.28 In particu-
lar, even if the membrane repair function was restored after rAAV 
transduction, the gene transfer was not associated with correction 
of the dysferlin deficient muscle histology or with the recovery of 
resistance to eccentric contractions.50 This suggests that some func-
tions supported by the missing dysferlin domains are required to 
fully restore the phenotype of dysferlin deficiency.
In summary, our results demonstrate that overlapping AAV vec-
tor transduction is a leading approach to safely restore full-length 




The full-length human dysferlin isoform 8 (NM_003494.3) cDNA was used 
in all cassettes of this study. The two cassettes for the concatemerization-
splicing strategy (Set 1), previously described in ref. 23, were composed as 
follows: the Set1 5’cassette includes a synthetic muscle-oriented promoter 
C5.12, a chimeric intron (β-globin), a consensus Kozak sequence (GCCACC), 
the exons 1 to 28 of dysferlin and the half intron 28 of dysferlin and the Set1 3’ 
cassette includes the second half of intron 28, the exons 29 to 55 and a SV40 
polyadenylation signal sequence. The cassettes Set2 were derived from Set1 
5’ and 3’ cassettes with the modification that the full length intron 28 of dys-
ferlin was added in the place of the half intron 28 in both plasmids. The two 
cassettes for the HR strategy, named Set3, were composed as follows: Set3_5’ 
includes the C5.12 promoter, a chimeric intron (β-globin), a consensus Kozak 
sequence (GCCACC) and the exons 1 to 30 and Set3_3’ includes the exons 24 
to 55 and a SV40 polyadenylation signal sequence. The region of homology 
between the two Set3 cassettes is of 859pb. A plasmid containing the C5.12 
promoter, a chimeric intron (β-globin), a consensus Kozak sequence, the full-
length dysferlin cDNA and a SV40 polyadenylation signal sequence was used 
for fAAV construct. All cassettes were pAAV2 and verified by sequencing.
Production of recombinant AAV
All recombinant AAV2/8 used in this study were produced using a triple 
transfection protocol and purified by two sequential cesium chloride 
(CsCl) density gradients. At the end of second centrifugation, 11 fractions 
of 500 µl were recovered from the CsCl Density Gradient tube and purified 
through dialysis in 1× PBS solution (ThermoScientific, Illkirch, France). For 
the Fragment batch 2 preparation, only fractions 2 and 3 of the second gra-
dient were pooled for the dialysis. Therefore, rAAVs used for systemic admin-
istration were enriched in large fragments. The fractions were analyzed by 
dot blot to determine those containing rAAV genomes. The viral genome 
number (vg) of each preparation was determined by quantitative real-time 
PCR-based titration method using primers and probe corresponding to the 
ITR region of the AAV vector genome.53
Alkaline agarose gel electrophoresis
An aliquot of each rAAV sample containing 6e10 vg was treated with DNase 
(Millipore, Molsheim, France) to remove any unprotected DNA. The cap-
sids were degraded during 10 minutes at 72 °C in the presence of protein-
ase K (Macherey-Nagel, Hoerdt, France). DNA was extracted with High Pure 
Viral Nucleic Acid kit and eluted in 50 µl of elution buffer (Roche, Boulogne-
Billancourt, France). All samples were denatured for 5 minutes at 95 °C and 
then immediately kept on ice for 5 minutes. To 15 µl of each sample, 3.1 µl of 
ethylenediaminetetraacetic acid (Roche) of 100 mmol/l were added; 3 µl of 
loading buffer 6× composed of 300 mmol/l NaOH, 6 mmol/l ethylenediamine-
tetraacetic acid, 18% ficoll, 0.5% bromocresol green and 0.25% xylene cyanol; 
and 1 µl of GelRed 20X (Biotium, Hayward, CA). The size-separation of samples 
was performed on an alkaline agarose gel (0.8% of agarose, 50 mmol/l NaOH 
and 1 mmol/l ethylenediaminetetraacetic acid) at 4 °C overnight at 18V. The 
GeneRuler DNA Ladder Mix (ThermoScientific) was used to determine the 
approximate molecular weights (MW) in kb of DNA in each of the bands. After 
30 minuteswash in TAE (Tris base, Acetic acid, EDTA (ethylenediaminetetraace-
tic acid)) ×, the gel was stained for 5H using GelRed diluted 1/10,000 in TAE 1×. 
A photograph of gel was performed for direct visualization of bands. The gel 
was transferred using the iBlot Dry Blotting System (ThermoScientific) onto 
a nylon membrane which was hybridized with a specific ITR probe labeled 
with the kit AlkPhos direct (Amersham Biosciences, GE Healthcare, Velizy-
Villacoublay, France). Detection was performed on a fluorescence Storm scan-
ner (100 µm, 650 V).
Animal models, vector administration, and functional evaluation
All procedures on animals were performed in accordance with the direc-
tive of 24 November 1986 (86/609/EEC) of the Council of the European 
Communities and were approved by Genethon’s ethics committee under 
the numbers CE11-013 and A-CE11-013. C57BL/6 mice were purchased from 
Charles River Laboratories (Les Oncins, France). B6.A-Dysfprmd (Dysfprmd) mice 
were obtained and bred at Généthon’s animal facility.
All experimental protocols were performed on 4-week-old male mice. IM 
injections were performed into the left TA muscle with 30 µl (1.3e10 vg per 
TA) of the rAAV viral preparation (alone or in equal proportion of each vector 
according to the vector set) or PBS (ThermoScientific). Systemic administra-
tions were performed by tail vein injections of 500 µl with different quanti-
ties of viral genome (9e13, 7.25e13, 4.5e13, 3e13, or 2.3e13 vg/kg) of a mix of 
the Set3rAAV viral preparations or PBS. The endpoint was 28 days or 1 year 
after injection.
The repetitive large-strain injury (LSI test) was performed in vivo on TA 
muscle.26,27 All mice were received an intraperitoneal injection with EBD 
(1 mg/g of body weight), 2 days after the LSI test. The mice were sacrificed 
24 hours after EBD injection and the TA muscles were removed and quickly 
frozen in liquid nitrogen-cooled isopentane.
Assessment of the whole body force by escape test
Global activity of mice was evaluated by escape test. Mice were placed on 
a platform facing the entrance of a tube that was 30 cm long. A cuff was 
wrapped around the tail and connected to a fixed force transducer. In 
response to a gentle pinching of the tail, mice tried to escape within the 
tube. A short peak of force was recorded by the force transducer and the test 
was performed five times. Maximal peak and the average of the five peaks 
normalized to animal body weight are reported.
RNA extraction and quantitative RT-PCR analysis
Total RNA was extracted from muscles lysates by the Trizol method 
(Life Technologies). The Free DNA kit (ThermoScientific) was used to 
remove residual DNA from the samples. One microgram of total RNA 
was reverse-transcribed using random hexamers and the Verso cDNA 
kit (ThermoScientific). Quantitative RT-PCR was performed with fol-
lowing primers and TaqMan probe: Exon28F: CTCAACCGGGCTGTCGAT, 
Exon29R: GTCGGTGTGTGTAGTACATCTTCTCA and Exons28/29 Probe: 
CAAGGCTGGGAG. The RH approaches (Set 3 and fAAV) do not allow design-
ing specific probe due to the large homologous region shared between 5’ 
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and 3’ parts. To validate the recombination, a RT-PCR was performed from 
RNA extracted from muscle of mice injected with both vectors using primers 
flanking the region of homology and the product was sequenced. Total RNA 
from an adult skeletal muscle served as quantification control (Stratagene, 
Agilent Biotechnologies, Les Ulis, France). The ubiquitous acidic ribosomal 
phosphoprotein (Rplp0) was used to normalize the data across samples.
Western blot analysis and enzyme-linked immunosorbent assay
Proteins were extracted from muscles, heart, or liver by cell lysis buffer 
(Pierce RIPA buffer, Thermo Scientific) and proteases inhibitors (Complete 
PIC, Roche) after homogenization with a FastPrep-24 (MP Biomedicals, 
Illkirch, France) in the Lysing Matrix A tubes (MP Biomedicals). Protein con-
centrations were determined by the BCA Protein Assay kit (Pierce, Thermo 
Scientific). The samples were prepared following the NuPAGE Tris-Acetate 
Gel protocol (Life Technologies). The proteins (100–120 µg) were sepa-
rated using a NuPAGE precast 3–8% Tris-Acetate gel (ThermoScientific) and 
then transferred to nitrocellulose membrane (Life Technologies) with iBlot 
Dry Blotting system (Life Technologies) using the P3 program for 8.5 min-
utes. Detection of dysferlin, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), or vinculin were performed using standard Odyssey protocol with 
primary specific monoclonal anti-dysferlin antibody: Mouse NCL-Hamlet 
(Novocastra, Leica Biosystems, Nanterre, France) diluted 1/200, Rabbit 
Romeo (Epitomics, Burlingame, CA) diluted 1:200, Rabbit anti–GAPDH (FL-
335) antibody (Santa Cruz Biotechnology, Heidelberg, Germany) diluted 
1:500, Mouse anti-Vinculin (Sigma) diluted 1: 500 and anti-actin; Rabbit 
(H-300; SantaCruz) diluted 1:500 or Mouse (ab11003; Abcam, Paris, France) 
diluted 1:500. Blot was revealed using the Odyssey secondary antibody 
goat anti mouse (GAM) 680, goat anti rabbit (GAR 680 and GAR 800 diluted 
1:5,000, scanned. Band density was quantified using the Image Studio Lite 
4.0 software (LI-COR Biosciences, Lincoln, NE). The integrated density of 
dysferlin was normalized by the vinculin’s, GAPDH’s or actin’s one.
Histology and immunohistochemistry
Cryosections (8–10-mm thickness) were prepared from frozen skeletal and 
cardiac muscles and formalin-fixed paraffin-embedded liver. Histological 
staining was performed with hematoxylin-phloxine-saffron.
Immunodetection was performed with the monoclonal antibody dysfer-
lin-Hamlet (NCL-Hamlet, diluted 1:50) as described previously28 or with the 
monoclonal dysferlin-Romeo (ab124684; Abcam) diluted 1:50. Mouse anti-
CD11b (550282; BD Biosciences; Le Pont de Claix, France); diluted 1:40 was 
used to detect inflammatory cells and RyR (ab2868; abcam) diluted 1:200 
was used to perform colocalization of dysferlin in T-tubules. Sections were 
mounted with DAPI-Fluoromount-G (Southern Biotech, Birmingham, AL) 
and examined under a confocal microscope Leica TCS SP2.
Evans Blue dye positive fibers were revealed by fluorescence excitation at 
633 nm on a Leica confocal fluorescent microscope on cryosections treated 
10 minutes in frozen acetone. Sections were mounted with Fluoromount-G 
(Southern Biotech) before the observation. The cartography of the whole 
section was performed using a motorized stage at an original 40x magni-
fication and using the software Cartograph (Microvision, Evry, France). The 
ratio of the area corresponding to the Evans Blue positive cells versus the 
whole area of the section was measured using Image J in the red channel.
Serum enzyme measurement
CK, ALAT, and ASAT activities in serum were measured with VITROS Slides 
(Ortho-Clinical Diagnostics, Rochester, NY).
Statistical analysis
Data for each group are represented as the means plus standard error of the 
mean. Differences between groups, compared one versus one, were deter-
mined using the Student’s t-test. Statistical significance was defined as P < 
0.001 (***), P < 0.01 (**), and P < 0.05 (*).
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